1. Home
  2. Programs
  3. ACC Action Center

Dapagliflozin reduces worsening HF in elderly TAVI patients

ACC Wayne Batchelor
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
  • Overview

    ACC.25 – Wayne Batchelor discusses the results of Dapa-TAVI. Compared with standard care, dapagliflozin reduced worsening of HF in elderly patients with aortic stenosis who underwent TAVI and were at high risk for HF events.

  • Educational information

    This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA. 

  • Faculty

    Wayne Batchelor is President of the Medicine Service Line at Inova Health System in Fairfax, VA, USA. He is also a professor at Duke University in Durham, NC, USA and chair of the ACC's Interventional Council.

  • Disclaimer

Recommended
Details
Presenters
  • Overview

    ACC.25 – Wayne Batchelor discusses the results of Dapa-TAVI. Compared with standard care, dapagliflozin reduced worsening of HF in elderly patients with aortic stenosis who underwent TAVI and were at high risk for HF events.

  • Educational information

    This video was recorded during the ACC.25 Scientific Session Chicago, IL, USA. 

  • Faculty

    Wayne Batchelor is President of the Medicine Service Line at Inova Health System in Fairfax, VA, USA. He is also a professor at Duke University in Durham, NC, USA and chair of the ACC's Interventional Council.

  • Disclaimer

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free